Pharma/Biotech Update: CSL Behring Opens Facility in Australia

Pharmaceutical company CSL Behring is making waves this week as they announced an expansion facilities.  Based in King of Prussia, Pennsylvania, the company is opening the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia.   The facility will be used for the late stage development of hemophilia products and  therapies for international clinical trials.

“This world-class facility is key to the ongoing success of our global R&D strategy and reflects our commitment to providing better treatment options for people who are managing certain bleeding disorders and other life-threatening conditions,” Paul Perreault,CEO of CSL Behring said in a press release.

Along with the news of a new facility also comes data presented at the current World Congress held by the World Federation of Hemophilia going on right now from May 11-15. Positive results were announced from current Phase I and II trials for a recombinant factor IX (9) product for hemophilia B.  The results showed that hemophilia B patients treated with the factor IX product required dosing only once every 14 days.

“Our interim PK data from two Phase III studies, combined with the Phase I and I/II results, demonstrate that rIX-FP (factor IX) has the potential to satisfy this unmet need by offering a longer dosing interval and fewer injections. Patients with hemophilia B and treating physicians are eager for innovative products that are able to decrease the dosing frequency while being effective and reliable in the prevention or treatment of bleeding episodes,” says Elena Santagostino, the study’s lead researcher.

Good news coming from CSL Behring on both the manufacturing, production and research end as well as the treatment options for those with hemophilia B.

Photo Credit – CSL Behring

webleed.org – your source for bleeding news!